The recent crystal structures of CC chemokine receptors 2 and 9 (CCR2 and CCR9) have provided structural evidence for an allosteric, intracellular binding site. The high conservation of residues involved in this site suggests its presence in most chemokine receptors, including the close homologue CCR1. By using
■ INTRODUCTION
Chemokines are chemotactic cytokines that control the migration and positioning of immune cells during physiological and pathological conditions by interacting with more than 20 different chemokine receptors. 1 Chemokine receptors mainly belong to the class A of G protein-coupled receptors (GPCRs) and can be divided into four different subtypes, namely C, CC, CXC, and CX3C, according to the pattern of specific cysteine residues in their major endogenous chemokines. 2 To exert their function, chemokines bind at the extracellular side of their receptors in a binding mechanism involving the Nterminal domain, extracellular loops, and the upper half of the transmembrane bundle. 3, 4 After activation, most chemokine receptors signal through heterotrimeric G proteins, mainly G i/o class, and β-arrestins.
2 CC chemokine receptors 1 (CCR1) and 2 (CCR2) are two of the 10 members of the CC subtype of chemokine receptors. CCR1 and CCR2 are expressed in a variety of immune cells, such as monocytes, dendritic cells, and T helper type-1 (T H 1) cells, from where they regulate diverse inflammatory and homeostatic functions. 5 Multiple chemokines activate these two receptors, including CCL3, CCL5, and CCL8 in the case of CCR1, and CCL2, CCL7, and CCL8 in the case of CCR2. 2 Dysregulation of CCR1, CCR2, and their ligands has been linked to several inflammatory and immune diseases, 6, 7 which has resulted in many drug discovery efforts to develop small molecules that target these receptors. 8, 9 Several lines of evidence support a role for both CCR1 and CCR2 in the pathogenesis of diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS): increased expression of both receptors and their ligands in disease models and patients, 10, 11 protective effect of genetic knockout of CCR1 or CCR2 in disease models, 12, 13 and positive preclinical studies with chemokineneutralizing monoclonal antibodies or small-molecule inhibitors of CCR1 or CCR2. 14−16 Yet, only few clinical studies have shown promising results, 17, 18 while most of the drugs developed so far have failed in clinical trials due to lack of efficacy. 8, 9 In this regard, the development of multitarget drugs has been proposed as a strategy to overcome the lack of efficacy. Multitarget drugs are designed to specifically act on more than one drug target, which might be necessary in highly heterogeneous diseases, such as RA and MS, where more than one chemokine receptor is involved. 19 The design of dual antagonists has been previously undertaken for CCR1/ CCR3, 20 CCR2/CCR5, 21 CCR5/CXCR4, 22 and CXCR1/ CXCR2; 23 however, no CCR1/CCR2 dual antagonists have so far been reported.
Recently, the crystal structures of CCR2 24 and CCR9 25 have revealed a novel allosteric binding site for small molecules in chemokine receptors. Both CCR2-RA- [R] in CCR2 and vercirnon in CCR9 bind in a pocket located in the intracellular surface of the receptors, partially overlapping with the binding site for G proteins and β-arrestins. 24, 25 These intracellular ligands can inhibit the receptors in a noncompetitive and insurmountable manner with regard to chemokine binding, as demonstrated previously in CCR2. 26 This might result in higher efficacy even in the presence of a high local concentration of chemokines during a disease state. Together with the potential advantages of allosteric modulators of chemokine receptors, this intracellular binding site seems to be quite conserved among chemokine receptors, which suggests the presence of homologous pockets in other receptors such as CCR1. 27 This conservation might provide an opportunity for the design of both selective and dual-targeting inhibitors of CCR1 and CCR2 as a novel approach to treat inflammatory and immune diseases.
For CCR2, several compounds belonging to different scaffolds have already been reported to bind to this intracellular binding site, including pyrrolone derivatives such as CCR2-RA-[R], sulfonamide derivatives, and 2-mercapto imidazoles. 26, 28 When tested for selectivity, some of these compounds also displayed a moderate activity on CCR1, 29−31 suggesting that they might also bind to CCR1. Thus, we selected the pyrrolone scaffold to explore a potential intracellular binding site in CCR1. In our current study, we report the synthesis and the biological evaluation of novel and previously patented pyrrolone derivatives 32, 33 at both CCR1 and CCR2 in order to determine their selectivity and structure−affinity relationships (SAR) for both receptors. Finally, compounds were tested in a [ 35 S]GTPγS binding assay in order to determine their functional effects in CCR1 and CCR2. Overall, our results provide evidence that CCR1 can also be targeted with intracellular allosteric modulators and that this binding site can be used for the design of multitarget compounds.
■ RESULTS AND DISCUSSION
Synthesis of Pyrrolone Derivatives. The racemic pyrrolones (6−24, 26−46) depicted in Scheme 1 were synthesized via a one-pot three-component condensation reaction, starting from the commercially available substituted aldehydes 1a−l, anilines 2a−q, and ethyl 2,4-dioxo-butanoates 3a−i in acetic acid 33 (6−23, 26−46) or THF 29 (24) . The ethyl 2,4-dioxo-butanoates (3b−d,f,i), which were not commercially available, were prepared by a Claisen condensation starting from the methyl ketones (4b−d,f,i) and diethyl oxalate 5. 34 Pyrrolone 25 was prepared via a transesterification of 24 by the use of p-toluenesulfonic acid in 2-propanol.
Characterization of [ 3 H]-CCR2-RA-[R] Binding on CCR1 and CCR2. [ 3 H]-CCR2-RA-[R] is the (R)-isomer of [
3 H]-CCR2-RA, a high-affinity radioligand previously characterized in our group for CCR2. 26 To avoid a possible effect of the lower-affinity isomer, we used the tritium-labeled (R)-isomer in the present study. As expected, [ 3 H]-CCR2-RA-[R] binds with high affinity to osteosarcoma (U2OS) cells stably expressing CCR2b (U2OS-CCR2) as shown by saturation experiments (K D of 6.3 nM and B max of 2.6 pmol/mg, Supporting Information, Figure S1 and Table S1 ). Kinetic characterization showed that [ Information,  Table S1 ), consistent with the previously reported [ 3 H]-CCR2-RA kinetics. 26 We had reported that [
3 H]-CCR2-RA binds with low affinity to CCR5 (K D of 100 nM), 28 suggesting that CCR2-RA-[R] is a nonselective antagonist that can bind several chemokine receptors. In this regard, CCR1 is a close homologue of CCR2, with 61% amino acid similarity and 47% identity; furthermore, this amino acid similarity is >90% when only considering the amino acid residues involved in the intracellular binding site of CCR2-RA- [R] in CCR2 24 (Supporting Information, Figure S2 in the homology models of CCR1 and CCR2, based on the crystal structure of CCR2 (PDB 5T1A). 24 For CCR1, representative residues are shown as green "sticks" and for CCR2 as orange "sticks". In all cases, oxygen and nitrogen atoms are represented in red and blue, respectively, and hydrogen bonds with dashed yellow lines. Residues are numbered based on the corresponding residue numbers and with structure-based Ballesteros−Weinstein numbers in superscript. 37 
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Article kinetic experiments at 25°C. These experiments showed that [ 3 H]-CCR2-RA-[R] associates and dissociates in a biphasic manner, similar to our findings in CCR2, but the association and dissociation rates were significantly higher in CCR1 than in CCR2 (Supporting Information, Figure S1 and Table S1 ).
Overall, these findings allowed us to set up a [ 3 H]-CCR2-RA-[R] competitive displacement assay on both U2OS-CCR1 and U2OS-CCR2 to determine the binding affinity (K i ) of unlabeled compounds. Using this assay, we first determined the ability of known ligands to displace this radioligand from CCR1, i.e., the CCR2 intracellular ligands SD-24 and JNJ-27141491 26, 28 and the CCR1 orthosteric antagonist BX471 with a pK i of 6.9 ± 0.06 (K i = 138 nM), consistent with previously reported activities in CCR1. 30, 31 To rule out that these compounds bind at the orthosteric binding site of CCR1, we also investigated the effect of BX471 in [ assay was also used to determine the affinity of the synthesized pyrrolone derivatives. All pyrrolone derivatives 6−46 were first tested at a single concentration of 1 μM in both U2OS-CCR1 and U2OS-CCR2 (Tables 1−3) . Compounds which displaced more than 50% of Docking of CCR2-RA-[R] in CCR1 and CCR2. To better understand the binding mode of CCR2-RA-[R] in both human CCR1 and CCR2b, we docked this compound into models of both receptors (Figure 2 ). In the case of CCR2, homology modeling was used to model the CCR2 residues between Ser226 5x62 and Lys240 6x32 , which correspond to the M2 muscarinic acetylcholine receptor sequence in the CCR2b crystal structure (PDB 5T1A). 24 These residues were modeled because this region is in close proximity to the CCR2-RA-[R] binding site. As expected from the sequence alignment (Supporting Information, Figure S2 ), CCR2-RA-[R] was predicted to bind to CCR1 in an overlapping binding site as 24 in a solvent-exposed intracellular pocket found between the intracellular ends of transmembrane segments 1−3, 6, 7, and helix 8 ( Figure 2 36 was selected as our starting point for the analysis of SAR in both CCR1 and CCR2. In our assay, compound 6 showed an affinity of 81 nM for CCR2 and a slightly higher affinity of 56 nM for CCR1 (Table 1) . To note, the binding affinities reported previously for these pyrrolone derivatives were obtained with a 125 I-CCL2 binding assay, 29, 36 resulting in lower affinities compared with our [ 3 H]-CCR2-RA-[R] binding assay, as previously observed in our group. 26 For our SAR study, we first examined different C5 substituents of the pyrrolone core (R 1 ), as shown in Table 1 . In line with previous studies, 29 we found that increasing the size of the cycloalkyl group from cyclohexyl (6) to cycloheptyl (7) or cyclooctyl (8) resulted in a decrease in binding affinity for CCR2; however, the affinity for CCR1 was retained, indicating that bulkier groups are better tolerated in CCR1 than in CCR2 and providing an avenue for selectivity on CCR1 over CCR2. Previous studies showed that decreasing the size of the cycloalkyl group was also detrimental for CCR2, 29 so we decided not to explore smaller ring sizes. Substitution of the cycloalkyl group by a phenyl group (9) led to a great loss of CCR2 affinity (39% displacement at 1 μM), consistent with previously reported values showing a decreased affinity for an almost similar pair of compounds. 36 Yet this substitution only led to a 3-fold decrease in CCR1 affinity (K i of 162 nM), thus showing much higher selectivity for CCR1. Next, we explored the effect of N-aryl modifications in both affinity and selectivity (compounds 10−17), specifically the effect of para and meta substituents. In general, N-aryl groups on the R 1 position resulted in increased selectivity toward CCR1, as most compounds did not displace more than 36% [ Furthermore, para-substituted derivatives displayed significantly higher affinities compared with their meta-substituted analogues.
In the case of CCR1, introduction of a para-methyl moiety (10) resulted in a slight decrease in affinity compared with the unsubstituted 9; in contrast, the meta-substituted analogue (14) showed less than 50% displacement at 1 μM. Introduction of an electron-donating substituent (methoxy, 11 and 15) was not well tolerated in any position, as it led to an approximately 3-fold decrease in affinity when placed in para position (11, 541 nM) and a near complete loss of affinity when placed in meta position (15, 28% displacement at 1 μM). Halogen substituents in para position were also more favored in the case of CCR1, yielding higher affinities compared with the unsubstituted 9 and regardless of the halogen used (67 nM for R 1 = 4-Cl phenyl (12), p < 0.0001 to 9; 87 nM for R 1 = 4-Br phenyl (13); p = 0.0002 to 9). However, selectivity for CCR1 was notably reduced considering that these compounds displayed binding affinities of around 200 nM in CCR2. Although moving the halogens to the meta position (16 and 17) decreased the affinities more than 2-fold compared with their para analogues, selectivity for CCR1 was restored as these compounds showed less than 20% displacement of [
Together, the results for compounds 6−17 indicate that in CCR1 aliphatic groups yield higher affinities, while aromatic groups yield lower affinities but improved selectivity over CCR2.
Modifications to the Acetyl Group (R 3 , Table 1 ). Previous modifications to the vinylogous carboxylic acid functionality in CCR2 showed detrimental effects in binding affinity. 29, 36 Indeed, mutagenesis and structural studies have shown crucial interactions of the hydroxyl and the two carbonyl groups with Glu310 8x48 , Lys311 8x49 , and Phe312 8x50 (residues according to structure-based Ballesteros−Weinstein numbering 37 ) in CCR2. 24, 28 Sequence alignment of CCR1 and CCR2 (Supporting Information, Figure S2 ) and our docking study ( Figure 2 ) suggest similar interactions in CCR1, as only position 8.49 differs (arginine in CCR1 and lysine in CCR2). Therefore, we decided to keep the vinylogous carboxylic acid moiety and explore different modifications to the acetyl group at the R 3 position (Table 1) . A gradual increase in the length of the alkyl chain from a methyl group (6) to a butyl group (18− 20) resulted in a ∼2-fold increase in CCR1 affinity (30 nM for R 3 = ethyl (18) , p = 0.0004 against 6; 29 nM for R 3 = propyl (19) , p = 0.0002 against 6; and 31 nM for R 3 = butyl (20) , p = 0.0010 against 6). In contrast, for CCR2, we observed a similar or a slight decrease in affinity. Introduction of a bulkier isopropyl group led to a decrease in affinity in both receptors, with a more drastic effect in CCR2 affinity. Replacing the isopropyl group with cyclopropyl (22) or tert-butyl (23) restored the affinity in CCR2 to values similar to compound 20 (22, 160 nM; 23, 158 nM); in CCR1, these modifications further improved the binding affinity to approximately 20 nM, yielding compounds with the highest affinity and selectivity observed in these series of R 1 and R 3 modifications (22, 19 nM; 23, 22 nM). These results suggest a larger hydrophobic subpocket in CCR1, able to accommodate larger and branched alkyl chains.
We also explored the effect of adding heteroatoms (oxygen in this case) between the carbonyl and an ethyl or isopropyl group (24 and 25, respectively). Overall, this led to a drastic drop in affinity for both receptors. This detrimental effect was most pronounced in compound 25, which displaced less than 40% of [ 3 H]-CCR2-RA-[R] binding in CCR1 and less than
Article 10% in CCR2. The transformation of the ketone into an ester might decrease the electron density on the carbonyl oxygen as well as the acidity of the adjacent protons, thus weakening or disrupting key hydrogen bonding interactions with Lys 8x49 in CCR2 24, 28 or Arg 8x49 in CCR1. The need of an acidic function for intracellular antagonists has also been reported in a study with N-benzylindole-2-carboxylic acids, where the authors found a correlation between higher acidity and higher CCR2 affinity. 38 Finally, replacing the methyl group in R 3 with a phenyl group (26) had no effect on CCR1 affinity, while it only displaced 37% of [
Altogether, these findings indicate that bigger, more lipophilic groups in R 3 are better tolerated in CCR1, while in CCR2 methyl is preferred.
Modifications to the Phenyl Ring (R 2 , Table 2 ). In addition, we explored different N-aryl modifications in the phenyl ring (R 2 , Table 2 ), starting with modifications in para position. Removing the methyl group in 6 yielded compound 27, with an unsubstituted phenyl group, which displaced less than 50% of the radioligand in both receptors. Increasing the size of the alkyl group from methyl (6) to ethyl (28) caused a 3-fold decrease in CCR1 affinity, while the affinity in CCR2 was maintained (28, 168 nM in CCR1 versus 66 nM in CCR2). Adding an electron-donating methoxy group was unfavorable for both receptors, as affinities dropped to 260 nM in CCR1 and 217 nM in CCR2. In contrast, an electron-withdrawing substituent (trifluoromethyl, 32) restored the affinity to 92 nM in CCR2, similar to our starting compound 6 and to 144 nM in CCR1. The substitution of the para-methyl group with halogens yielded derivatives with improved binding affinities in both receptors (30 and 31) but no gain in selectivity. Substitution with a chlorine (30) or bromine atom (31) led to a 4.5-fold increase in CCR2 affinity compared with 6, with K i values around 20 nM regardless of the halogen. In the case of CCR1, the bromine atom (31) led to a 2-fold increase compared with 6 (31, 24 nM), while the smaller chlorine atom did not affect the affinity much (30, 40 nM). Although not synthesized in our study, Dasse et al. (2007) 29 showed that the para-fluoro analogue performed worse in CCR2 than other para-halogen derivatives. In this regard, from fluoro to chloro there is an important increase in polarity (σ), lipophilicity (π), and size, whereas from chloro to bromo only lipophilicity and size increase. 39, 40 Taken together, these results suggest that lipophilicity and size of the halogen might be more important in CCR1 than in CCR2, while electronegativity or polarity could play a bigger role in CCR2.
Moving the substituents from the para to the meta position resulted in poor affinities for both receptors compared with their para-substituted analogues. In CCR1, the meta-methyl (33) and meta-chlorine (35) groups led to a 9-fold and 13-fold decrease in affinity, respectively; in CCR2, the affinities decreased 3-fold and 13-fold after the same substitutions. The addition of a trifluoromethyl group in meta position (36) also led to a 3-fold decrease in CCR2 affinity compared with its para-substituted analogue 32. In CCR1, 36 only displaced 25% of
binding at a concentration of 1 μM, displaying the highest selectivity toward CCR2 in these series of modifications. Also detrimental was the addition of a fluorine group in meta position (34) , which led to less than 50% displacement of [ 
Article introduce different substituents in the ortho position were unsuccessful, thus we continued to explore different combinations of phenyl substituents.
As part of our SAR analysis, we synthesized compound 38 (also referred as CCR2-RA), which corresponds to the racemic mixture of the radioligand [
3 H]-CCR2-RA-[R] used in this study. This compound displayed an affinity of 15 nM in CCR1 and 11 nM in CCR2, similar to the K D values obtained in homologous displacement or saturation assays (Supporting Information, Table S1 ). Replacing the para-chloro group in 38 with a methyl moiety (37) , while keeping the ortho-fluorine group, led to an expected decrease in affinity for both receptors, as compound 6 with a methyl group in para position performed worse than 30 with a chlorine atom in the same position. When the para substituent was replaced with a bromine atom (39), the affinity was restored to 11 nM in CCR1 and 6 nM in CCR2. Subsequent combinations of meta and para substituents (40−42) generated compounds with decreased CCR1 affinities compared with 38, as expected from the data on the monosubstituted meta analogues. Compound 41 displayed a slightly higher selectivity for CCR2 (9 nM in CCR2 versus 31 nM in CCR1). Overall, disubstituted derivatives performed better than the monosubstituted compounds in both receptors; however, no clear trend in selectivity was observed in these series.
In an attempt to improve both affinity and selectivity for CCR1, we decided to combine some of the best features observed at R 1 , R 2 , and R 3 positions: a disubstituted phenyl ring with an ortho-fluoro and para-bromo moieties for R 2 in order to retain the high affinity of 39, a cyclopropyl group or an unsubstituted phenyl ring at R 3 (22 and 26) to gain selectivity, and a meta-bromo phenyl ring at R 1 (17) to further improve selectivity for CCR1. These combinations resulted in four final compounds shown in Table 3 (43−46 ). To maintain a high affinity for CCR1, we kept the 2-fluoro-4-bromophenyl group at R 2 constant, and we combined it with different R 1 and R 3 substituents. The combination with a cyclopropyl group at R 3 position (43) led to the highest CCR1 affinity in our study (K i of 5 nM), but selectivity over CCR2 was reduced compared with 22 (3-fold versus 8-fold Figure 3a) . Using the same assay conditions, we characterized the G protein activation of CCL3 in U2OS-CCR1 membranes. In this assay, CCL3 induced [
35 S]GTPγS binding in CCR1 with a higher potency than CCL2 in CCR2 (1.3 nM, pEC 50 = 8.9 ± 0.06) and with a higher maximum effect (E max ) (Figure 3a ). It should be noted that the potency of CCL3 in our study is lower than previously reported, 41 which might be related to the differences in cell line and/or assay conditions.
For the antagonist assays, we used a submaximal EC 80 concentration of CCL3 (8 nM) and CCL2 (20 nM) in CCR1 or CCR2, respectively, in order to evoke 80% stimulation of [ 35 S]GTPγS binding. Although all compounds were able to inhibit CCL3-or CCL2-induced G protein activation, their potencies (IC 50 ) ranged between 30 nM to 8 μM (Table 4 and Figure 3b,c) . In CCR2, the potency of the compounds increased in the same order observed for affinity (Figure 3c , 45 < 43 < 41 < 39). In CCR1, 39 displayed the highest potency (590 nM), followed by 43 (950 nM), contrary to their binding affinity (Figure 3b, 43 > 39) . In addition, the moderate selectivity observed in the binding assays was lost in this functional assay: except for 45, all compounds were more potent inhibitors of CCR2 than CCR1, as their potencies were 3-fold (43) 26 In contrast, all compounds displayed at least a 50-fold difference between assays when tested on CCR1. Such lack of correlation between apparent potencies and binding affinities in CCR1 might be dependent on the assay conditions used, G protein concentrations, or the chemokine 
Article used in this study; thus, further studies are warranted to fully characterize these ligands for their selectivity.
In CCR1, all compounds behaved as inverse agonists, as they all significantly decreased the basal activity of CCR1 at the highest concentration tested (Supporting Information, Figure  S3a ). In this regard, it was previously demonstrated that CCR1 exhibits constitutive activity leading to ligand-independent G protein-activation, β-arrestin recruitment, and receptor internalization, 42 which points to the development of inverse agonists as a potential therapeutic option for inflammatory diseases. Yet, only BX-471 35 has been reported to act as inverse agonist in CCR1. 42 This prompted us to further characterize these compounds as inverse agonists in CCR1 by measuring their inhibitory potency in absence of the agonist CCL3 (Supporting Information, Figure S3b and Table S2 ). Compounds 39 and 41 were more potent inverse agonists than antagonists, displaying a 3-fold and almost 10-fold higher potency, respectively, as inverse agonists. As such, their potencies as inverse agonists were more comparable to their binding affinities (Table 2 and Supporting Information, Table  S2 ). In contrast, 43 and 45 showed similar potencies when measured in the absence or presence of CCL3 and thus displayed more than 130-fold difference between functional and binding assays (Table 2 and Supporting Information,  Table S2 ) (Table 4 and Supporting Information, Table S2 ), indicative of a more complex mechanism of inhibition, combining negative allosteric modulation and inverse agonism. 43 Of note, the basal levels of constitutive activity in the [ Figure  S3a ). However, no constitutive activity has been reported for CCR2, with only one constitutively active mutant (CAM) described so far. 44 In fact, Gilliland et al. (2013) showed that CCR2 was not able to induce ligand-independent cell migration or to constitutively associate with β-arrestin, pointing to a lack of constitutive activity. 42 Moreover, several classes of orthosteric and allosteric CCR2 ligands did not show evidence of inverse agonism when previously tested in a similar [ 35 S]GTPγS binding assay. 26 Thus, the inverse agonism observed in this study might be the consequence of the expression level, ligand concentration, and/or assay conditions employed, so further research is warranted to investigate ligand-independent signaling in CCR2.
■ CONCLUSIONS
In this study, we have characterized [
, a high-affinity intracellular antagonist previously described for CCR2, 26 in both CCR1 and CCR2, which allowed us to conclude that this radioligand binds to CCR1 with a similar high affinity. By characterizing this radioligand in CCR1, we have provided evidence that CCR1 possesses an intracellular binding site that can be used for the design of noncompetitive compounds. In addition, this intracellular radioligand allowed us to explore the SAR of a series of pyrrolone derivatives in both CCR1 and CCR2. Although some of these derivatives had been previously described for CCR2, their characterization in CCR1 had not been reported. With the SAR analysis we learned that introduction of bulkier and more lipophilic groups 
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Article at R 1 and R 3 positions was better tolerated in CCR1, allowing us to obtain better selectivity for this receptor. The high conservation between the intracellular pockets of CCR1 and CCR2 prevented us from finding high selectivity in these series of compounds but allowed us to find several potential dualtarget antagonists. Finally, characterization of four selected compounds in a functional assay allowed us to determine their functional effects as antagonists in CCR2 and inverse agonists in the constitutively active CCR1, which opens up a novel avenue to modulate these receptors in inflammatory diseases. In addition, this highly conserved binding site might allow the design of both selective and multitarget inhibitors for chemokine receptors beyond CCR1 and CCR2.
■ EXPERIMENTAL SECTION
Chemistry: General Methods. All solvents and reagents were purchased from commercial sources and were of analytical grade. Demineralized water is simply referred to as H 2 O, as was used in all cases unless stated otherwise (i.e., brine). conditions were not optimized. Additionally, all compounds were screened using FAF-Drugs4 45, 46 in order to detect potential pan-assay interference compounds (PAINS). None of the compounds was identified as PAINS after application of three different filters based on Baell et al. 47 General Procedure for the Synthesis of Compounds 6−23, 26−46. 33 The respective aldehyde 1a−l (1.0 equiv), aniline 2a−q (1.0 equiv), and ethyl 2,4-dioxo-butanoate analogue 3a−i (1.0 equiv) were dissolved in acetic acid (2.5 mL/mmol) and heated at 95°C for 2−4 h under a nitrogen atmosphere. Upon completion of the reaction (TLC 1/7 EtOAct/petroleum ether), acetic acid was removed under reduced pressure, the residue was triturated with Et 2 O and stirred for 30 min, after which the pure product was collected by filtration.
4-Acetyl-5-cyclohexyl-3-hydroxy-1-(4-methylphenyl)-1,5-dihydro-2H-pyrrol-2-one (6)
. 33 Started from cyclohexane carboxaldehyde 1a (243 μL, 2.00 mmol, 1.00 equiv), 4-methylaniline (214 mg, 2.00 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (251 μL, 2.00 mmol, 1.00 equiv) in 5 mL of acetic acid. Yield: 287 mg, 46%, white solid. 1 . 32 Started from cycloheptylcarboxaldehyde 1b 48 (375 mg, 3.00 mmol, 1.00 equiv), 4-methylaniline 2b (321 mg, 3.00 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (377 μL, 3.00 mmol, 1.00 equiv) in 7.5 mL of acetic acid. Purified by recrystallization from a mixture of EtOAc and petroleum ether. Yield: 102 mg, 13%, off-white solid. 1 
4-Acetyl-5-cyclooctyl-3-hydroxy-1-(4-methylphenyl)-1,5-dihydro-2H-pyrrol-2-one (8).
32 Started from cyclooctylcarboxaldehyde 1c (648 mL, 4.42 mmol, 1.00 equiv), 4-methylaniline 2b (474 mg, 4.42 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554 μL, 4.42 mmol, 1.00 equiv) in 10 mL of acetic acid. Purified by column chromatography using as eluent 1/6 EtOAc/petroleum ether. Yield: 118 mg, 8%, white solid. 4-Acetyl-3-hydroxy-5-(4-methoxyphenyl)-1-(4-methylphenyl)-1,5-dihydro-2H-pyrrol-2-one (11). 49 Started from 4-methoxybenzaldehyde 1f (527 mL, 4.42 mmol, 1.00 equiv), 4-methylaniline 2b (474 mg, 4.42 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554 μL, 4.42 mmol, 1.00 equiv) in 10 mL of acetic acid. The desired product was obtained by column chromatography using a gradient of 1/6 EtOAc/petroleum ether to 1/3 EtOAc/petroleum ether, yielding 34 mg, 2% as an off-white solid. (12) . 32 Started from 4-chlorobenzaldehyde 1g (621 mg, 4.42 mmol, 1.00 equiv), 4-methylaniline 2b (474 mg, 4.42 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554 μL, 4.42 mmol, 1.00 equiv) in 10 mL of acetic acid. The desired product was obtained by column chromatography using 1/6 EtOAc/ petroleum ether as eluent, yielding 96 mg, 6% as a white solid. (14) . Started from 3-methylbenzaldehyde 1i (600 mg, 5.00 mmol, 1.00 equiv), 4-methylaniline 2b (536 mg, 5.00 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (627 μL, 5.00 mmol, 1.00 equiv) in 12 mL of acetic acid. Yield: 560 mg, 35%, white solid. 5-Cyclohexyl-3-hydroxy-1-(4-methylphenyl)-4-pivaloyl-1,5-dihydro-2H-pyrrol-2-one (23). 32 Started from cyclohexane carboxaldehyde 1a (121 μL, 1.00 mmol, 1.00 equiv), 4-methylaniline 2b (107 mg, 1.00 mmol, 1.00 equiv), and ethyl 5,5-dimethyl-2,4-dioxohexanoate 3g (175 μL, 1.00 mmol, 1.00 equiv) in 3 mL of acetic acid. Yield: 20 mg, 6%, white solid. 29 Sodium 1,4-diethoxy-1,4-dioxobut-2-en-2-olate (1.25 g, 6.00 mmol) was dissolved in 25 mL of H 2 O, and 25 mL of Et 2 O was added. The mixture was acidified to
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Article pH 2 with 6 M HCl (aq) and was extracted with Et 2 O from the aqueous phase, dried over MgSO 4 , and concentrated in vacuo, yielding 1.05 g, 4.97 mmol, 83% diethyl 2-oxosuccinate as a yellow oil. 52 Diethyl 2-oxosuccinate 3h (1.05 g, 4.97 mmol, 1.12 equiv) was added to a mixture of cyclohexane carboxaldehyde 1a (534 μL, 4.42 mmol, 1.00 equiv) and 4-methylaniline 2b (474 mg, 4.42 mmol, 1.00 equiv) in 10 mL of dry THF and stirred at room temperature overnight. The reaction mixture was concentrated in vacuo, Et 2 O was added, and the white precipitate was collected by filtration. Yield: 400 mg, 26%, white solid. 1 Ester 22 (343 mg, 1 .00 mmol, 1.00 equiv) and p-toluenesulfonic acid (172 mg, 1.00 mmol, 1.00 equiv) were dissolved in 10 mL of 2-propanol, and the reaction mixture was refluxed for 48 h. The solvent was removed under reduced pressure, and the crude product was dissolved in 50 mL of EtOAc and washed 3× with H 2 O, dried over MgSO 4 , filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (4/1 EtOAc/petroleum ether) and yielded 150 mg, 9.5%, brownish solid. (27) . 32 Started from cyclohexane carboxaldehyde 1a (534 μL, 4.42 mmol, 1.00 equiv), aniline 2a (400 μL, 4.42 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554 μL, 4.42 mmol, 1.00 equiv) in 10 mL of AcOH. Yield: 1.00 g, 76%, yellow solid. 4-Acetyl-5-cyclohexyl-3-hydroxy-1-(4-methoxyphenyl)-1,5-dihydro-2H-pyrrol-2-one (29) . 32 Started from cyclohexane carboxaldehyde 1a (534 μL, 4.42 mmol, 1.00 equiv), 4-methoxyaniline 2d (560 mg, 4.42 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554 μL, 4.42 mmol, 1.00 equiv) in 10 mL of AcOH. Yield: 805 mg, 56%, light-yellow solid. (39) . 32 Started from cyclohexane carboxaldehyde 1a (303 μL, 2.50 mmol, 1.00 equiv), 4-bromo-2-fluoroaniline 2n (475 μL, 2.50 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (395 μL, 2.50 mmol, 1.00 equiv) in 5 mL of AcOH. Purified by silica column chromatography using EtOAc/ petroleum ether (1/6). The resulting impure product was stirred in diisopropylether, and the pure product was obtained by filtration. Yield: 36 mg, 4%, white solid. (40) . 32 Started from cyclohexane carboxaldehyde 1a (303 μL, 2.50 mmol, 1.00 equiv), 3,4-dimethylaniline 2o (303 μL, 2.50 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (395 μL, 2.50 mmol, 1.00 equiv) in 5 mL of AcOH. Yield: 167 mg, 20%, white solid. 1-(4-Bromo-2-fluorophenyl)-5-cyclohexyl-4-(cyclopropanecarbonyl)-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one (43) . Started from cyclohexane carboxaldehyde 1a (242 μL, 2.00 mmol, 1.00 equiv), 4-bromo-2-fluoroaniline 2n (380 mg, 2.00 mmol, 1.00 equiv), and ethyl 4-cyclopropyl-2,4-dioxobutanoate 51 3f (368 mg, 2.00 mmol, 1.00 equiv) in 5 mL of AcOH. Yield: 240 mg, 28%, white solid. (46) . Started from 3-bromobenzaldehyde 1l (291 μL, 2.50 mmol, 1.00 equiv), 4-bromo-2-fluoroaniline 2n (475 mg, 2.50 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (395 mg, 2.50 mmol, 1.00 equiv) in 5 mL of AcOH. Purified by silica column chromatography using EtOAc/ petroleum ether (1/19 , SD-24, and JNJ-27141491 were synthesized as described previously. 30, 36, 54 BX471 was purchased from Cayman Chemical (Ann Arbor, MI, USA). Chemokine ligands CCL2 and CCL3 were purchased from PeproTech (Rocky Hill, NJ). Bovine serum albumin (BSA, fraction V) was purchased from Sigma (St. Louis, MO, USA). Bicinchoninic acid (BCA) and BCA protein assay reagent were purchased from Pierce Chemical Company (Rockford, IL, USA). Tango CCR1-bla and Tango CCR2-bla osteosarcoma (U2OS) cells stably expressing the human CCR1 or human CCR2b (U2OS-CCR1 or U2OS-CCR2, respectively) were obtained from Invitrogen (Carlsbad, CA). All other chemicals were obtained from standard commercial sources.
Cell Culture and Membrane Preparation. U2OS-CCR1 and U2OS-CCR2 were grown in a humidified atmosphere at 37°C and 5% CO 2 in McCoy's 5A medium supplemented with 10% fetal calf serum, 2 mM glutamine, 0.1 mM nonessential amino acids (NEAAs),
Article 25 mM HEPES, 1 mM sodium pyruvate, 100 IU/ml penicillin, 100 μg/mL streptomycin, 100 μg/mL G418, 50 μg/mL hygromycin, and 125 μg/mL zeocin (200 μg/mL zeocin for U2OS-CCR1). Cells were subcultured twice a week at a ratio of 1:3 to 1:8 on 10 cm Ø plates by trypsinization. For membrane preparation cells were subcultured on 15 cm Ø plates using dialyzed fetal calf serum. Membranes from U2OS-CCR1 and U2OS-CCR2 cells were prepared as described previously. 26 Briefly, cells were detached from confluent 15 cm Ø plates by scraping them into 5 mL of phosphate-buffered saline (PBS), collected, and centrifuged for 5 min at 3000 rpm (700g). The pellets were resuspended in ice-cold 50 mM Tris-HCl buffer, pH 7.4, supplemented with 5 mM MgCl 2 , and homogenized with an Ultra Turrax homogenizer (IKA-Werke GmbH & Co. KG, Staufen, Germany). Membranes were separated from the cytosolic fraction by several centrifugation steps in an Optima LE-80 K ultracentrifuge (Beckman Coulter, Inc., Fullerton, CA) at 31000 rpm for 20 min at 4°C
. Finally, the membrane pellets were resuspended in 50 mM TrisHCl buffer supplemented with 5 mM MgCl 2 , pH 7.4, divided into aliquots of 100 μL and 250 μL, and stored at −80°C. Membrane protein concentrations were measured using a BCA protein determination with BSA as a standard. For all experiments, incubations were terminated by dilution with ice-cold wash buffer (50 mM Tris-HCl buffer supplemented with 5 mM MgCl 2 and 0.05% CHAPS, pH 7.4). Separation of bound from free radioligand was performed by rapid filtration through a 96-well GF/B filter plate using a PerkinElmer Filtermate harvester (PerkinElmer, Groningen, The Netherlands). Filters were washed 10 times with ice-cold wash buffer. Then 25 μL of Microscint scintillation cocktail (PerkinElmer, Groningen, The Netherlands) was added to each well and the filter-bound radioactivity was determined by scintillation spectrometry using the P-E 2450 Microbeta 2 scintillation plate counter (PerkinElmer, Groningen, The Netherlands).
[ 35 S]GTPγS Binding Assays. [ 35 S]GTPγS binding assays were performed as described previously. 26 Briefly, binding assays were performed in a 100 μL reaction volume containing assay buffer (50 mM Tris-HCl, 5 mM MgCl 2 , 100 mM NaCl, 1 mM EDTA, and 0.05% BSA, pH 7.4), 10 μM GDP, 10 μg of saponin, and 10 μg of membrane, either U2OS-CCR1 or U2OS-CCR2. To determine the EC 50 value of CCL2 and CCL3, the membrane mixture was preincubated with increasing concentrations of chemokine for 30 min at 25°C. To determine the IC 50 values of the ligands, the membrane mixture was preincubated with increasing concentrations of the ligand of interest in the absence or presence of a fixed concentration of CCL2 (20 nM) or CCL3 (8 nM The observed association rate constants (k obs,fast ; k obs,slow ) were calculated by fitting the data to a two-phase exponential association function; similarly, dissociation rate constants (k off,fast ; k off,slow ) were calculated using a two-phase exponential decay function. All values obtained are means ± standard error of the mean (SEM) of at least three independent experiments performed in duplicate, unless stated otherwise. Differences in kinetic rates and pIC 50 values between receptors or between assay formats (in the absence or presence of chemokine) were analyzed using an unpaired, two-tailed Student's ttest with Welch's correction; differences in pK i values between compounds, in maximal [ S]GTPγS inhibition curves against compound 45, which showed a pseudo-Hill slope of approximately unity, were analyzed using a one-way ANOVA with Dunnett's posthoc test. Significant differences are displayed as *, p < 0.05; **, p < 0.01; ***, p < 0.001; and ****, p < 0.0001.
Computational Receptor Modeling and Docking. All modeling was performed in the Schrodinger suite, 57 Figure 3b,c were made in a later version 58 that includes the interaction and orientation of residues (e.g., backbone, side chain). As a starting point for the structure-based studies we used the recently published crystal structure of CCR2b in complex with both BMS-681 and CCR2-RA-[R] (PDB 5T1A). 24 We replaced the sequence (CCR2b: sequence between L226 5x62 and R240 6x32 ) of the M2 muscarinic acetylcholine receptor, close to the intracellular binding site, by the CCR2b sequence using homology modeling 59−61 and CCR5 as template (PDB 4MBS). 62 A homology model of CCR1 was constructed on the basis of this CCR2b model. For both models, the knowledge-based scoring function was used. For the ligand docked, the pK a of the hydroxyl hydrogen was calculated to be 4.5 using Jaguar; 63, 64 therefore, the negatively charged protonation state was used. Compound CCR2-RA-[R] was docked in both models using Induced Fit docking. 65, 66 Visualizations were created using PyMOL; 67 
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